These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

674 related articles for article (PubMed ID: 19203346)

  • 41. Analysis of gene expression profiles in an imatinib-resistant cell line, KCL22/SR.
    Ohmine K; Nagai T; Tarumoto T; Miyoshi T; Muroi K; Mano H; Komatsu N; Takaku F; Ozawa K
    Stem Cells; 2003; 21(3):315-21. PubMed ID: 12743326
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia.
    Chen R; Gandhi V; Plunkett W
    Cancer Res; 2006 Nov; 66(22):10959-66. PubMed ID: 17108134
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Resistance to Fas-mediated apoptosis in malignant tumours is rescued by KN-93 and cisplatin via downregulation of c-FLIP expression and phosphorylation.
    Yang BF; Xiao C; Li H; Yang SJ
    Clin Exp Pharmacol Physiol; 2007 Dec; 34(12):1245-51. PubMed ID: 17973862
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Imatinib resistance in multidrug-resistant K562 human leukemic cells.
    Assef Y; Rubio F; Coló G; del Mónaco S; Costas MA; Kotsias BA
    Leuk Res; 2009 May; 33(5):710-6. PubMed ID: 18977528
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sonic hedgehog signaling regulates Bcr-Abl expression in human chronic myeloid leukemia cells.
    Liao HF; Su YC; Zheng ZY; Jhih Cai C; Hou MH; Chao KS; Chen YJ
    Biomed Pharmacother; 2012 Jul; 66(5):378-83. PubMed ID: 22397755
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Alantolactone induces apoptosis in chronic myelogenous leukemia sensitive or resistant to imatinib through NF-κB inhibition and Bcr/Abl protein deletion.
    Wei W; Huang H; Zhao S; Liu W; Liu CX; Chen L; Li JM; Wu YL; Yan H
    Apoptosis; 2013 Sep; 18(9):1060-70. PubMed ID: 23613107
    [TBL] [Abstract][Full Text] [Related]  

  • 47. BCR-ABL- and Ras-independent activation of Raf as a novel mechanism of Imatinib resistance in CML.
    Hentschel J; Rubio I; Eberhart M; Hipler C; Schiefner J; Schubert K; Loncarevic IF; Wittig U; Baniahmad A; von Eggeling F
    Int J Oncol; 2011 Sep; 39(3):585-91. PubMed ID: 21637917
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inhibition of RIP and c-FLIP enhances TRAIL-induced apoptosis in pancreatic cancer cells.
    Wang P; Zhang J; Bellail A; Jiang W; Hugh J; Kneteman NM; Hao C
    Cell Signal; 2007 Nov; 19(11):2237-46. PubMed ID: 17693058
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Regulation of the resistance to TRAIL-induced apoptosis in human primary T lymphocytes: role of NF-kappaB inhibition.
    Morales JC; Ruiz-Magaña MJ; Ruiz-Ruiz C
    Mol Immunol; 2007 Apr; 44(10):2587-97. PubMed ID: 17257681
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy.
    Jilani I; Kantarjian H; Gorre M; Cortes J; Ottmann O; Bhalla K; Giles FJ; Albitar M
    Leuk Res; 2008 Apr; 32(4):643-9. PubMed ID: 17900686
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Proteasome proteolytic profile is linked to Bcr-Abl expression.
    Crawford LJ; Windrum P; Magill L; Melo JV; McCallum L; McMullin MF; Ovaa H; Walker B; Irvine AE
    Exp Hematol; 2009 Mar; 37(3):357-66. PubMed ID: 19157685
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Rapid up-regulation of c-FLIP expression by BCR signaling through the PI3K/Akt pathway inhibits simultaneously induced Fas-mediated apoptosis in murine B lymphocytes.
    Moriyama H; Yonehara S
    Immunol Lett; 2007 Mar; 109(1):36-46. PubMed ID: 17275920
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Gene therapy for BCR-ABL+ human CML with dual phosphorylation resistant p27Kip1 and stable RNA interference using an EBV vector.
    Sengupta A; Banerjee D; Chandra S; Banerjee S
    J Gene Med; 2006 Oct; 8(10):1251-61. PubMed ID: 16952195
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Valproate enhances imatinib-induced growth arrest and apoptosis in chronic myeloid leukemia cells.
    Morotti A; Cilloni D; Messa F; Arruga F; Defilippi I; Carturan S; Catalano R; Rosso V; Chiarenza A; Pilatrino C; Guerrasio A; Taulli R; Bracco E; Pautasso M; Baraban D; Gottardi E; Saglio G
    Cancer; 2006 Mar; 106(5):1188-96. PubMed ID: 16444746
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Design, synthesis, and biological evaluation of novel water-soluble triptolide derivatives: Antineoplastic activity against imatinib-resistant CML cells bearing T315I mutant Bcr-Abl.
    Xu F; Shi X; Li S; Cui J; Lu Z; Jin Y; Lin Y; Pang J; Pan J
    Bioorg Med Chem; 2010 Mar; 18(5):1806-15. PubMed ID: 20149665
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Sensitization of human K562 leukemic cells to TRAIL-induced apoptosis by inhibiting the DNA-PKcs/Akt-mediated cell survival pathway.
    Kim MJ; Kim HB; Bae JH; Lee JW; Park SJ; Kim DW; Park SI; Kang CD; Kim SH
    Biochem Pharmacol; 2009 Sep; 78(6):573-82. PubMed ID: 19464267
    [TBL] [Abstract][Full Text] [Related]  

  • 57. RAC3 down-regulation sensitizes human chronic myeloid leukemia cells to TRAIL-induced apoptosis.
    Colo GP; Rosato RR; Grant S; Costas MA
    FEBS Lett; 2007 Oct; 581(26):5075-81. PubMed ID: 17927986
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571.
    Koyama N; Koschmieder S; Tyagi S; Portero-Robles I; Chromic J; Myloch S; Nürnberger H; Rossmanith T; Hofmann WK; Hoelzer D; Ottmann OG
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2025-31. PubMed ID: 16609011
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cathepsin B release after imatinib-mediated lysosomal membrane permeabilization triggers BCR-ABL cleavage and elimination of chronic myelogenous leukemia cells.
    Puissant A; Colosetti P; Robert G; Cassuto JP; Raynaud S; Auberger P
    Leukemia; 2010 Jan; 24(1):115-24. PubMed ID: 19924144
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
    Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
    Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.